Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBITDA (2020 - 2025)

Historic EBITDA for IDEAYA Biosciences (IDYA) over the last 6 years, with Q3 2025 value amounting to $119.8 million.

  • IDEAYA Biosciences' EBITDA rose 35719.9% to $119.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3465.55%. This contributed to the annual value of -$274.2 million for FY2024, which is 15037.16% down from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' EBITDA is $119.8 million, which was up 35719.9% from -$133.3 million recorded in Q4 2024.
  • In the past 5 years, IDEAYA Biosciences' EBITDA ranged from a high of $119.8 million in Q3 2025 and a low of -$133.3 million during Q4 2024
  • For the 5-year period, IDEAYA Biosciences' EBITDA averaged around -$22.1 million, with its median value being -$22.9 million (2022).
  • In the last 5 years, IDEAYA Biosciences' EBITDA tumbled by 227479.87% in 2023 and then surged by 35719.9% in 2025.
  • IDEAYA Biosciences' EBITDA (Quarter) stood at -$18.9 million in 2021, then decreased by 22.23% to -$23.1 million in 2022, then plummeted by 41.5% to -$32.6 million in 2023, then plummeted by 308.47% to -$133.3 million in 2024, then soared by 189.83% to $119.8 million in 2025.
  • Its EBITDA stands at $119.8 million for Q3 2025, versus -$133.3 million for Q4 2024 and -$46.6 million for Q3 2024.